MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG
- 8 October 2018
- journal article
- research article
- Published by Springer Nature in Nature Chemical Biology
- Vol. 14 (11) , 1032-1042
Abstract
α-Ketoglutarate (αKG) is a key node in many important metabolic pathways. The αKG analog N-oxalylglycine (NOG) and its cell-permeable prodrug dimethyloxalylglycine (DMOG) are extensively used to inhibit αKG-dependent dioxygenases. However, whether NOG interference with other αKG-dependent processes contributes to its mode of action remains poorly understood. Here we show that, in aqueous solutions, DMOG is rapidly hydrolyzed, yielding methyloxalylglycine (MOG). MOG elicits cytotoxicity in a manner that depends on its transport by monocarboxylate transporter 2 (MCT2) and is associated with decreased glutamine-derived tricarboxylic acid–cycle flux, suppressed mitochondrial respiration and decreased ATP production. MCT2-facilitated entry of MOG into cells leads to sufficiently high concentrations of NOG to inhibit multiple enzymes in glutamine metabolism, including glutamate dehydrogenase. These findings reveal that MCT2 dictates the mode of action of NOG by determining its intracellular concentration and have important implications for the use of (D)MOG in studying αKG-dependent signaling and metabolism.Keywords
This publication has 60 references indexed in Scilit:
- Glutamine‐driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxiaMolecular Systems Biology, 2013
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- Breathless cancer cells get fat on glutamineCell Research, 2012
- Inhibition of 2-oxoglutarate dependent oxygenasesChemical Society Reviews, 2011
- Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenasesTrends in Biochemical Sciences, 2011
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolismNature Genetics, 2008
- How many drug targets are there?Nature Reviews Drug Discovery, 2006
- A General Approach to Detect Protein Expression In Vivo Using Fluorescent Puromycin ConjugatesChemistry & Biology, 2004
- Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivativesJournal of Medicinal Chemistry, 1992